United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions
UTHR Stock Forecast
United Therapeutics stock forecast is as follows: an average price target of $358.20 (represents a -2.49% downside from UTHR’s last price of $367.36) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
UTHR Price Target
The average price target for United Therapeutics (UTHR) is $358.20 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $575.00 to $215.00. This represents a potential -2.49% downside from UTHR's last price of $367.36.
UTHR Analyst Ratings
According to 7 Wall Street analysts, United Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for UTHR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
United Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Jasper Hellweg | Argus Research | $400.00 | $362.36 | 10.39% | 8.89% |
| Oct 31, 2024 | Andrew Fein | H.C. Wainwright | $425.00 | $361.40 | 17.60% | 15.69% |
| Sep 23, 2024 | Eun Yang | Jefferies | $432.00 | $353.00 | 22.38% | 17.60% |
| Aug 28, 2024 | Hartaj Singh | Oppenheimer | $575.00 | $362.44 | 58.64% | 56.52% |
| Jul 08, 2024 | Ashwani Verma | UBS | $370.00 | $317.18 | 16.65% | 0.72% |
| Jun 12, 2024 | Tiago Fauth | Wells Fargo | $350.00 | $275.76 | 26.92% | -4.73% |
| May 02, 2024 | Hartaj Singh | Oppenheimer | $400.00 | $255.14 | 56.78% | 8.89% |
| Feb 12, 2024 | Chris Shibutani | Goldman Sachs | $215.00 | $214.74 | 0.12% | -41.47% |
| Jan 11, 2023 | - | Argus Research | $300.00 | $263.41 | 13.89% | -18.34% |
| Dec 06, 2022 | - | Morgan Stanley | $330.00 | $276.07 | 19.53% | -10.17% |
The latest United Therapeutics stock forecast, released on Oct 31, 2024 by Jasper Hellweg from Argus Research, set a price target of $400.00, which represents a 10.39% increase from the stock price at the time of the forecast ($362.36), and a 8.89% increase from UTHR last price ($367.36).
United Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 8 |
| Avg Price Target | $412.50 | $458.00 | $395.88 |
| Last Closing Price | $367.36 | $367.36 | $367.36 |
| Upside/Downside | 12.29% | 24.67% | 7.76% |
In the current month, the average price target of United Therapeutics stock is $412.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 12.29% increase as opposed to United Therapeutics's last price of $367.36. This month's average price target is down -9.93% compared to last quarter, and up 4.20% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 21, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 21, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 23, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 23, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 23, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 20, 2024 | UBS | Underperform | Underperform | Hold |
| Aug 20, 2024 | Wells Fargo | Buy | Buy | Hold |
United Therapeutics's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave UTHR a "Buy" rating, the same as its previous rate.
United Therapeutics Financial Forecast
United Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $609.40M | - | $506.90M | $491.50M | $516.00M | $466.90M | $461.90M | $415.20M | $444.70M | $446.50M | $379.10M | $384.60M | $380.10M | $362.00M | $356.30M | $311.10M | $401.50M | $373.60M | $362.60M | $389.20M | $370.50M |
| Avg Forecast | $840.42M | $831.46M | $800.05M | $757.42M | $739.92M | $722.62M | $691.87M | $620.31M | $575.01M | $585.82M | $524.18M | $514.37M | $519.21M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M | $332.15M | $335.43M | $245.96M | $315.26M |
| High Forecast | $885.97M | $876.52M | $843.42M | $760.07M | $812.93M | $724.84M | $691.87M | $620.31M | $610.36M | $603.74M | $552.58M | $542.25M | $547.35M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M | $332.15M | $335.43M | $295.15M | $378.31M |
| Low Forecast | $804.96M | $796.38M | $766.30M | $754.75M | $698.19M | $720.39M | $691.87M | $620.31M | $538.02M | $561.00M | $502.06M | $492.67M | $497.30M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M | $332.15M | $335.43M | $196.77M | $252.21M |
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | - | 0.99% | 0.95% | 1.05% | 1.01% | 1.10% | 0.97% | 1.06% | 1.18% | 1.03% | 1.06% | 1.06% | 1.06% | 1.03% | 0.87% | 1.19% | 1.12% | 1.08% | 1.58% | 1.18% |
United Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $575.01M, with a low forecast of $538.02M, and a high forecast of $610.36M. UTHR's average Quarter revenue forecast represents a -5.64% decrease compared to the company's last Quarter revenue of $609.40M (Sep 23).
United Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $327.00M | - | $319.00M | $191.10M | $334.60M | $169.50M | $327.60M | $157.80M | $221.40M | $233.60M | $49.60M | $-117.50M | $235.70M | $152.10M | $192.20M | $90.80M | $191.30M | $273.00M | $-630.00M | $319.50M | $272.30M |
| Avg Forecast | $328.48M | $324.98M | $312.70M | $296.04M | $289.20M | $282.44M | $270.42M | $106.50M | $224.74M | $228.97M | $204.87M | $96.82M | $237.51M | $181.35M | $169.53M | $88.02M | $157.22M | $154.96M | $139.19M | $80.02M | $133.12M | $131.80M | $125.01M | $166.34M | $131.55M | $124.13M | $122.13M | $-3.44B | $146.77M | $224.59M |
| High Forecast | $346.28M | $342.59M | $329.65M | $297.08M | $317.73M | $283.31M | $270.42M | $127.80M | $238.56M | $235.97M | $215.98M | $116.19M | $285.01M | $181.35M | $169.53M | $105.62M | $157.22M | $154.96M | $139.19M | $96.02M | $133.12M | $131.80M | $125.01M | $199.61M | $131.55M | $124.13M | $122.13M | $-2.75B | $176.12M | $269.50M |
| Low Forecast | $314.62M | $311.27M | $299.51M | $294.99M | $272.89M | $281.57M | $270.42M | $85.20M | $210.28M | $219.27M | $196.23M | $77.46M | $190.00M | $181.35M | $169.53M | $70.42M | $157.22M | $154.96M | $139.19M | $64.01M | $133.12M | $131.80M | $125.01M | $133.07M | $131.55M | $124.13M | $122.13M | $-4.13B | $117.42M | $179.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.43% | - | 3.29% | 0.80% | 1.85% | 1.00% | 3.72% | 1.00% | 1.43% | 1.68% | 0.62% | -0.88% | 1.79% | 1.22% | 1.16% | 0.69% | 1.54% | 2.24% | 0.18% | 2.18% | 1.21% |
8 analysts predict UTHR's average Quarter EBITDA for Dec 23 to be $224.74M, with a high of $238.56M and a low of $210.28M. This is -31.27% lower than United Therapeutics's previous annual EBITDA (Sep 23) of $327.00M.
United Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $267.60M | - | $240.90M | $132.10M | $239.30M | $116.00M | $239.90M | $112.20M | $162.70M | $172.60M | $28.30M | $98.00M | $171.20M | $107.10M | $137.70M | $52.60M | $132.40M | $205.10M | $-494.60M | $244.50M | $178.60M |
| Avg Forecast | $377.84M | $400.87M | $384.30M | $351.67M | $318.94M | $315.73M | $314.86M | $60.77M | $202.66M | $246.93M | $221.14M | $55.24M | $168.87M | $185.70M | $208.49M | $50.22M | $170.05M | $170.64M | $143.45M | $45.66M | $140.18M | $134.96M | $131.71M | $119.17M | $125.45M | $120.65M | $117.74M | $-2.70B | $112.32M | $147.30M |
| High Forecast | $404.46M | $429.12M | $411.37M | $355.89M | $395.87M | $315.82M | $315.36M | $72.92M | $256.43M | $275.61M | $236.72M | $66.29M | $202.65M | $185.70M | $208.49M | $60.27M | $170.05M | $170.64M | $143.45M | $54.79M | $140.18M | $134.96M | $131.71M | $143.01M | $125.45M | $120.65M | $117.74M | $-2.16B | $134.78M | $176.77M |
| Low Forecast | $357.12M | $378.89M | $363.22M | $346.94M | $256.27M | $315.64M | $314.37M | $48.61M | $153.55M | $194.92M | $209.01M | $44.19M | $135.10M | $185.70M | $208.49M | $40.18M | $170.05M | $170.64M | $143.45M | $36.52M | $140.18M | $134.96M | $131.71M | $95.34M | $125.45M | $120.65M | $117.74M | $-3.24B | $89.85M | $117.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | - | 4.36% | 0.78% | 1.29% | 0.56% | 4.78% | 0.66% | 0.95% | 1.20% | 0.62% | 0.70% | 1.27% | 0.81% | 1.16% | 0.42% | 1.10% | 1.74% | 0.18% | 2.18% | 1.21% |
United Therapeutics's average Quarter net income forecast for Dec 23 is $202.66M, with a range of $153.55M to $256.43M. UTHR's average Quarter net income forecast represents a -24.27% decrease compared to the company's last Quarter net income of $267.60M (Sep 23).
United Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $127.60M | - | $87.30M | $166.10M | $98.40M | $141.50M | $79.00M | $127.90M | $109.10M | $112.80M | $117.20M | $103.80M | $66.30M | $105.90M | $93.00M | $105.20M | $99.40M | $39.60M | $92.00M | $-6.60M | $56.40M |
| Avg Forecast | $210.34M | $208.10M | $200.24M | $189.57M | $185.19M | $180.86M | $173.16M | $251.66M | $143.91M | $146.62M | $131.19M | $228.78M | $192.50M | $123.44M | $115.39M | $207.98M | $107.02M | $105.48M | $94.75M | $189.07M | $90.61M | $89.72M | $85.09M | $80.49M | $89.54M | $84.50M | $83.13M | $83.95M | $-3.03M | $46.52M |
| High Forecast | $221.74M | $219.38M | $211.09M | $190.23M | $203.46M | $181.41M | $173.16M | $301.99M | $152.76M | $151.10M | $138.30M | $274.54M | $231.00M | $123.44M | $115.39M | $249.58M | $107.02M | $105.48M | $94.75M | $226.89M | $90.61M | $89.72M | $85.09M | $96.58M | $89.54M | $84.50M | $83.13M | $83.95M | $-2.43M | $55.82M |
| Low Forecast | $201.47M | $199.32M | $191.79M | $188.90M | $174.74M | $180.30M | $173.16M | $201.33M | $134.65M | $140.41M | $125.66M | $183.02M | $154.00M | $123.44M | $115.39M | $166.39M | $107.02M | $105.48M | $94.75M | $151.26M | $90.61M | $89.72M | $85.09M | $64.39M | $89.54M | $84.50M | $83.13M | $83.95M | $-3.64M | $37.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | - | 0.38% | 0.86% | 0.80% | 1.23% | 0.38% | 1.20% | 1.03% | 1.19% | 0.62% | 1.15% | 0.74% | 1.24% | 1.16% | 1.17% | 1.18% | 0.48% | 1.10% | 2.18% | 1.21% |
United Therapeutics's average Quarter SG&A projection for Dec 23 is $143.91M, based on 8 Wall Street analysts, with a range of $134.65M to $152.76M. The forecast indicates a 12.78% rise compared to UTHR last annual SG&A of $127.60M (Sep 23).
United Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $5.71 | - | $5.20 | $2.88 | $5.26 | $2.56 | $5.31 | $2.49 | $3.62 | $3.85 | $0.63 | $2.22 | $3.86 | $2.43 | $3.14 | $1.20 | $3.02 | $4.68 | $-11.32 | $5.65 | $4.01 |
| Avg Forecast | $7.81 | $8.28 | $7.94 | $7.27 | $6.59 | $6.52 | $6.51 | $5.74 | $4.19 | $5.10 | $4.57 | $4.59 | $4.72 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 | $2.48 | $2.72 | $1.62 | $2.73 |
| High Forecast | $8.36 | $8.87 | $8.50 | $7.35 | $8.18 | $6.53 | $6.52 | $5.76 | $5.30 | $5.69 | $4.89 | $4.91 | $5.06 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 | $2.48 | $2.72 | $1.94 | $3.28 |
| Low Forecast | $7.38 | $7.83 | $7.50 | $7.17 | $5.29 | $6.52 | $6.50 | $5.72 | $3.17 | $4.03 | $4.32 | $4.34 | $4.46 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 | $2.48 | $2.72 | $1.29 | $2.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | - | 1.13% | 0.61% | 1.35% | 0.58% | 1.46% | 0.70% | 1.01% | 1.27% | 0.21% | 0.75% | 1.36% | 0.88% | 1.15% | 0.45% | 1.19% | 1.89% | -4.17% | 3.49% | 1.47% |
According to 8 Wall Street analysts, United Therapeutics's projected average Quarter EPS for Dec 23 is $4.19, with a low estimate of $3.17 and a high estimate of $5.30. This represents a -26.67% decrease compared to UTHR previous annual EPS of $5.71 (Sep 23).
United Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.73 | $33.86 | 1857.23% | Buy |
| LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| RARE | Ultragenyx Pharmaceutical | $46.02 | $106.93 | 132.36% | Buy |
| REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
| LEGN | Legend Biotech | $39.75 | $82.69 | 108.03% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.09 | $36.33 | 72.26% | Buy |
| MNKD | MannKind | $6.90 | $11.00 | 59.42% | Buy |
| ASND | Ascendis Pharma | $122.64 | $190.21 | 55.10% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| PCVX | Vaxcyte | $88.39 | $124.00 | 40.29% | Buy |
| BGNE | BeiGene | $194.56 | $255.80 | 31.48% | Buy |
| NUVL | Nuvalent | $92.73 | $111.57 | 20.32% | Buy |
| INCY | Incyte | $70.39 | $84.56 | 20.13% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.80 | $254.21 | 3.00% | Buy |
| UTHR | United Therapeutics | $367.36 | $358.20 | -2.49% | Buy |